Terug
12
Dagbereik
€ 16,83
€ 25,33
52-Weeksbereik
€ 16,83
€ 25,33
Volume
200
50D / 200D Gem.
€ 16,83
/
€ 16,83
Vorige Slotkoers
€ 16,83
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,0 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 11,6 | 3,8 |
| Net Margin % | 7,3 | 3,9 |
| Rev Growth 5Y % | 13,8 | 10,0 |
| D/E | 1,4 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 505,87
€ 493,34 – € 514,34
|
330 B | 1 |
| FY2029 |
€ 476,25
€ 464,45 – € 484,23
|
330 B | 1 |
| FY2028 |
€ 440,93
€ 430,01 – € 448,32
|
310 B | 1 |
Belangrijkste Punten
Revenue grew 13,78% annually over 5 years — strong growth
Earnings grew 17,39% over the past year
ROE of 11,59% — decent returns on equity
Negative free cash flow of -7,82B
P/E of 0,04 — trading at a low valuation
PEG of 0,54 suggests growth is underpriced
Groei
Revenue Growth (5Y)
13,78%
Revenue (1Y)13,89%
Earnings (1Y)17,39%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
11,59%
ROIC4,33%
Net Margin7,31%
Op. Margin8,95%
Veiligheid
Debt / Equity
1,35
Current Ratio2,81
Interest Coverage14,29
Waardering
P/E Ratio
0,04
P/B Ratio0,00
EV/EBITDA8,02
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 13,89% | Revenue Growth (3Y) | 11,49% |
| Earnings Growth (1Y) | 17,39% | Earnings Growth (3Y) | 193,70% |
| Revenue Growth (5Y) | 13,78% | Earnings Growth (5Y) | 7,99% |
| Profitability | |||
| Revenue (TTM) | 259,59B | Net Income (TTM) | 18,99B |
| ROE | 11,59% | ROA | 4,03% |
| Gross Margin | 36,49% | Operating Margin | 8,95% |
| Net Margin | 7,31% | Free Cash Flow (TTM) | -7,82B |
| ROIC | 4,33% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,35 | Current Ratio | 2,81 |
| Interest Coverage | 14,29 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 0,04 | P/B Ratio | 0,00 |
| P/S Ratio | 0,00 | PEG Ratio | 0,54 |
| EV/EBITDA | 8,02 | Dividend Yield | 0,02% |
| Market Cap | 828,51M | Enterprise Value | 186,34B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 259,59B | 227,93B | 208,86B | 165,62B | 154,90B |
| Net Income | 18,99B | 16,17B | 2,20B | 15,91B | 13,96B |
| EPS (Diluted) | 385,71 | 328,59 | 44,72 | 316,19 | 271,93 |
| Gross Profit | 94,73B | 81,38B | 72,71B | 70,19B | 65,45B |
| Operating Income | 23,24B | 17,65B | 5,51B | 19,21B | 19,92B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 470,82B | 430,65B | 371,35B | 329,94B | 245,67B |
| Total Liabilities | 299,20B | 274,76B | 234,45B | 197,77B | 129,07B |
| Shareholders' Equity | 171,62B | 155,89B | 136,89B | 132,17B | 116,60B |
| Total Debt | 230,98B | 202,36B | 173,07B | 144,13B | 84,77B |
| Cash & Equivalents | 45,47B | 29,65B | 24,26B | 32,83B | 22,92B |
| Current Assets | 247,31B | 217,72B | 182,99B | 166,86B | 137,29B |
| Current Liabilities | 87,94B | 80,12B | 78,53B | 115,07B | 51,52B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#540 of 616
Recente Activiteit
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026